Takeda Pharmaceutical Li... (TKPHF)
OTC: TKPHF
· Real-Time Price · USD
29.45
0.00 (0.00%)
At close: Aug 13, 2025, 11:10 AM
29.45
0.00%
After-hours: Aug 13, 2025, 08:00 PM EDT
Takeda Pharmaceutical Income Statement
Financials in JPY. Fiscal
year is
April - March.
| Fiscal Year | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
Revenue | 1,106.7B | 1,053.4B | 1,144.1B | 1,176B | 1,208B | 1,050.9B | 1,111.2B | 1,043.1B | 1,058.6B | 956.16B | 1,096.6B | 1,002.3B | 972.47B | 873.29B | 901.29B | 844.82B | 949.6B | 770.27B | 836.75B | 788.93B | 801.85B |
Cost of Revenue | 384.68B | 382.08B | 416.87B | 394.31B | 549.78B | 382.5B | 379.48B | 343.58B | 321.11B | 309.77B | 335.97B | 305.44B | 292.88B | 308.38B | 281.4B | 275.8B | 241.26B | 253.45B | 253.14B | 249.64B | 238.08B |
Gross Profit | 722.01B | 671.32B | 727.25B | 781.73B | 658.21B | 668.37B | 731.71B | 699.51B | 737.5B | 646.38B | 760.58B | 696.86B | 679.58B | 564.91B | 619.89B | 569.02B | 708.34B | 516.83B | 583.61B | 539.29B | 563.77B |
Operating Income | 184.57B | -74.93B | 66.94B | 184.25B | 166.33B | 187.28B | 104.91B | -49.34B | 168.57B | 88.56B | 146.99B | 104.44B | 150.51B | -1.62B | 116.48B | 97.43B | 248.55B | 150.54B | 143.14B | 48.3B | 167.28B |
Interest Income | 73.76B | -8.17B | -6.99B | 4.12B | 30.68B | 5.99B | 21.79B | 9.36B | 26.45B | 7.78B | 41.68B | 14.78B | 60.92B | n/a | 4.14B | 6.86B | 45.85B | 47.49B | 28.4B | 10.02B | 19.61B |
Pretax Income | 150.63B | -107.3B | 26.41B | 119.37B | 136.6B | -51.26B | 61.26B | -95.98B | 135.03B | 47.91B | 107.15B | 64.55B | 155.47B | -54.05B | 72.19B | 61.45B | 222.98B | 130.88B | 109.8B | -4.73B | 130.29B |
Net Income | 124.24B | -103.16B | 23.79B | 92.05B | 95.25B | -3.02B | 105.72B | -48.03B | 89.39B | 31.13B | 119.13B | 61.74B | 105.01B | -11.36B | 57.77B | 45.96B | 137.68B | 197.1B | 92.36B | 4.04B | 82.51B |
Selling & General & Admin | 255.88B | 295.87B | 270.59B | 268.28B | 270.03B | 285.23B | 267.52B | 252.95B | 248.11B | 254.8B | 262.3B | 248.73B | 231.48B | 223.43B | 231.08B | 212.01B | 219.84B | 234.39B | 222.64B | 216.26B | 202.37B |
Research & Development | 143.89B | 216.01B | 170.19B | 175.56B | 168.46B | 195.86B | 187.38B | 183.95B | 162.74B | 160.94B | 174.63B | 154.15B | 143.61B | 143.63B | 128.38B | 131.6B | 122.48B | 113.29B | 117.57B | 118.16B | 106.82B |
Other Expenses | 137.67B | 234.38B | 219.53B | 153.63B | 216.21B | n/a | -1.21B | n/a | n/a | n/a | -1.01B | n/a | n/a | n/a | n/a | -1.52B | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 537.44B | 746.25B | 660.31B | 597.48B | 654.71B | 481.09B | 665.29B | 748.85B | 568.93B | 557.82B | 613.59B | 592.42B | 529.07B | 566.53B | 503.4B | 471.6B | 459.79B | 366.29B | 440.47B | 490.99B | 396.49B |
Interest Expense | 107.16B | -22.43B | 31.6B | 68.45B | 59.69B | 47.19B | 66.57B | 46.52B | 59.58B | 42.93B | 79.75B | 53.8B | 55.47B | n/a | 46.71B | 39.68B | 71.07B | 75.24B | 62.67B | 63.87B | 46.85B |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 922.12B | 1,128.3B | 1,077.2B | 991.79B | 1,041.7B | 863.59B | 1,044.8B | 1,092.4B | 890.05B | 867.59B | 949.56B | 897.87B | 821.95B | 874.91B | 784.81B | 747.39B | 701.05B | 619.73B | 693.61B | 740.63B | 634.57B |
Income Tax Expense | 26.35B | -4.2B | 2.57B | 27.27B | 41.3B | -44.53B | -44.5B | -48.01B | 45.63B | 16.78B | -12B | 2.82B | 50.45B | -42.67B | 14.37B | 15.45B | 85.25B | -66.27B | 17.36B | -8.8B | 47.77B |
Shares Outstanding (Basic) | 1.56B | 1.58B | 1.58B | 1.58B | 1.59B | 1.57B | 1.57B | 1.57B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.57B | 1.57B | 1.55B | 1.57B | 1.56B | 1.56B | 1.56B |
Shares Outstanding (Diluted) | 1.59B | 1.58B | 1.61B | 1.61B | 1.59B | 1.57B | 1.59B | 1.57B | 1.57B | 1.61B | 1.57B | 1.56B | 1.55B | 1.55B | 1.57B | 1.58B | 1.55B | 1.57B | 1.58B | 1.57B | 1.57B |
EPS (Basic) | 79.40 | -65.25 | 15.03 | 58.14 | 59.94 | -1.92 | 67.38 | -30.68 | 57.51 | 20.03 | 76.63 | 39.77 | 67.92 | -7.31 | 36.91 | 29.24 | 89.08 | 125.19 | 59.08 | 2.58 | 52.93 |
EPS (Diluted) | 78.23 | -65.25 | 14.78 | 57.17 | 59.94 | -1.92 | 66.70 | -30.68 | 57.12 | 19.29 | 75.86 | 39.48 | 67.56 | -7.31 | 36.68 | 29.08 | 88.58 | 125.18 | 58.61 | 2.57 | 52.68 |
EBITDA | 439.42B | 73.35B | 244.96B | 380.28B | 384.55B | 86.09B | 291.98B | 133.35B | 347.9B | 252.26B | 323.87B | 272.26B | 323.04B | 121.3B | 263.77B | 238.07B | 391.55B | 126.99B | 282.89B | 187.25B | 293.06B |
EBIT | 257.79B | -129.73B | 58B | 187.83B | 196.29B | -100.65B | 127.83B | -37.96B | 194.61B | 38.12B | 186.9B | 118.35B | 210.94B | -75.15B | 118.9B | 101.12B | 294.05B | 54.12B | 172.47B | 59.14B | 177.14B |
Depreciation & Amortization | 181.64B | 203.07B | 186.96B | 192.45B | 192.22B | 186.74B | 187.06B | 182.7B | 171.5B | 161.41B | 176.88B | 167.83B | 158.28B | 152.27B | 147.28B | 140.65B | 142.95B | 72.87B | 139.75B | 138.94B | 141.59B |